SELLAS Life Sciences Group, Inc.

SELLAS Life Sciences Group, Inc., a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. Its lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase III clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. The company also develops nelipepimut-S, a cancer immunotherapy that targets human epidermal growth factor receptor 2, which is in Phase 2b clinical trials for the treatment of early-stage breast cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors. The company was founded in 2012 and is headquartered in New York, New York.

NASDAQ:SLS

SELLAS Life Sciences Group, Inc.

Last Close

1.16

26/07 20:00

Market Cap

67.00M

Beta: 2.25

Volume Today

321.55K

Avg: 476.91K

PE Ratio

−0.45

PFCF: −0.72

locale

market

industry

website

ipo date

peer of

Earnings

Earnings per Share (Estimate*)

Revenue (Estimate*)

Metrics